Odona.aiodona.ai

ALK-Abelló A/S (ALK B.CO)

scorecard multi-axes · Scorecard agent
243.6 DKK
Avg target 287.5 · +18%
as of 2026-10-28 · 06:25 PM
Radar
70 / 100
Tactical · 1–3 months
Favorable · short term
75 / 100
Strategic · 3 months +
Favorable · long term
computed from 5 of 6 axes
n/a: score not calculated
The long-term case and current setup for ALK-Abelló are aligned, driven by robust fundamentals and strong structural tailwinds in the allergy immunotherapy market. While analyst consensus is unanimously positive, the stock's valuation appears to reflect much of the immediate upside. A key risk remains the evolving competitive intensity within the broader biotechnology sector.
Analysts — consensus & targets
strong_buy6 analysts
6 buy · 0 hold · 0 sell

Analysts maintain a unanimous 'Strong Buy' rating, projecting an 18% implied upside to the average target, reflecting confidence in ALK-Abelló's growth prospects and market position.

HIGH300MID287.5LOW270 LAST 243.6
Trends by horizon log-price channels ±2σ
1Y +2% · R² 0.00
3M +8% · R² 0.11
1M +26% · R² 0.89
Strengths · watch · risks
Strengths
  • Strong profitability and consistent revenue growth.
  • Healthy balance sheet with low debt.
  • Unanimous analyst "Strong Buy" consensus.
  • Favorable structural tailwinds in allergy treatment market.
Watch
  • RSI indicates stock approaching overbought levels.
  • Recent trading volume below average.
Risks
  • Increasing competitive intensity in biotechnology sector.
  • Upside potential largely priced into current valuation.
  • Limited public data on customer loyalty and retention.
Detail by axis
Fundamentals 76
weight · tac 10 | strat 45
ALK-Abelló exhibits strong profitability with a 19.86% profit margin and robust growth, evidenced by 17.6% revenue growth and 25% earnings growth. The balance sheet is healthy, showing a low debt-to-equity ratio of 6.08% and ample cash reserves.
Valuation56
Profitability75
Growth78
Balance sheet93
Yahoo Finance financials · 7/7 ratios · 2026-10-28
Macro & sector 80
weight · tac 5 | strat 15
The biotechnology sector, particularly allergy immunotherapy, is experiencing strong structural tailwinds with projected CAGRs of 7.6% to 12.2% through 2033. While competitive intensity is noted, the overall market expansion provides a favorable environment for growth.
The Business Research Company, Research and Markets, Coherent Market Insights, EY
Chart / technical 66
weight · tac 30 | strat 0
The stock is trading above its 20, 50, and 200-day simple moving averages, indicating a positive short-to-medium term trend. However, the RSI of 70.37 suggests it is approaching overbought territory, and recent volume is below average.
Yahoo Finance daily prices · 5/5 indicators · last close 2026-10-28
Momentum & consensus 73
weight · tac 25 | strat 15
The company benefits from unanimous analyst support with all six analysts rating it a Strong Buy, implying an 18% upside to the average target. This strong consensus reflects positive market sentiment and potential for continued price momentum.
Yahoo Finance · 6 analysts · 3-month return
News & Social 67
weight · tac 25 | strat 10
Five relevant news articles were scored over the past 35 days, with the newest on 2026-10-19. This indicates a consistent, positive news flow contributing to the score.
Odona news feed · 5 articles over 35 days · newest 2026-10-19
Customers n/a
insufficient data · excluded from the composite
No disclosed customer concentration, contract terms, renewal record, or specific market share data for ALK-Abelló A/S was found. Customer loyalty metrics such as NPS or retention rates were also not available in aggregate form.
No aggregate customer evidence found.
Sources
Factual analysis from public research — not personalised investment advice and not a recommendation. Scores are structured reference points, not forecasts. Odona is a decision-support tool.
Press coverage — deep dive

Summary. ALK-Abelló A/S, a leader in allergy solutions, demonstrates robust financial health and operates within a growing market. The company's strong fundamentals and positive sector outlook are key drivers, though its current valuation and competitive landscape warrant attention. This scorecard examines the company's performance across six axes, highlighting its strategic position and tactical considerations.

Earnings and Financials

ALK-Abelló showcases strong financial performance, with profit margins of 19.86% and gross margins at 68.18%. The company reported impressive revenue growth of 17.6% and earnings growth of 25%, underpinned by a robust balance sheet featuring a low debt-to-equity ratio of 6.08% and substantial cash reserves. This indicates efficient operations and sound financial management.

Competition and Macro

The biotechnology sector, particularly allergy immunotherapy, benefits from significant structural tailwinds, with market reports projecting annual growth rates between 7.6% and 12.2% through 2033. This expanding market provides a favorable environment for ALK-Abelló. However, the sector also faces increasing competitive intensity, as highlighted by industry outlooks, which could impact future market share dynamics.

Catalysts and Valuation

Analyst sentiment is overwhelmingly positive, with all six covering analysts issuing a 'Strong Buy' rating and an average price target implying an 18% upside. However, with the current price at 243.6 DKK and an average target of 287.5 DKK, much of this upside appears to be priced in. The company trades at a trailing P/E of 39.9x and a forward P/E of 33.2x.